KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 10 years of Cost of Revenue data on record, last reported at $26.2 million in Q4 2025.

  • For Q4 2025, Cost of Revenue rose 20.28% year-over-year to $26.2 million; the TTM value through Dec 2025 reached $89.0 million, up 8.75%, while the annual FY2025 figure was $89.0 million, 8.75% up from the prior year.
  • Cost of Revenue reached $26.2 million in Q4 2025 per ACAD's latest filing, up from $21.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $26.2 million in Q4 2025 and bottomed at $1.7 million in Q1 2023.
  • Average Cost of Revenue over 5 years is $12.1 million, with a median of $12.7 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: tumbled 77.54% in 2022, then surged 1276.78% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $10.7 million in 2021, then crashed by 77.54% to $2.4 million in 2022, then skyrocketed by 641.44% to $17.9 million in 2023, then rose by 21.87% to $21.8 million in 2024, then increased by 20.28% to $26.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $26.2 million in Q4 2025, $21.6 million in Q3 2025, and $20.7 million in Q2 2025.